Home » Flamel Terminates Biovail License Pact
Flamel Terminates Biovail License Pact
French biopharmaceutical firm Flamel Technologies SA said it terminated the company's license agreement with Biovail Laboratories Inc. for Genvir, Flamel's oral controlled-release form of acyclovir for the treatment of genital herpes. Flamel's American depositary receipts fell 18 cents to close at $16.18 on the Nasdaq, but plunged $1.59, or 9.8 percent, to $14.59 in after-market activity.
Forbes (http://www.forbes.com/associatedpress/feeds/ap/2005/03/03/ap1862300.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May